Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

Summary

Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.

Timeline

Start

2022-12-19

Primary completion

2023-12-15

Completion

2024-01-25

Outcome

Met primary endpoint

registry analysis (superiority test); Aceclidine + Brimonidine (LNZ101); p <0.0001; Odds Ratio (OR) 7.52; Generalized Estimating Equation (GEE) NCT05656027 ↗

Drugs

Indications